Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

MRD-guided zanubrutinib, venetoclax, and obinutuzumab in relapsed CLL: primary end point analysis from the CLL2-BZAG trial

Blood (2025) 145 (12): 1282–1292.

https://doi.org/10.1182/blood.2024026685

Published: 2025

Includes: Supplemental data

Journal Articles

Prediction of Poor Outcome in CLL Patients Treated with FCR (Fludarabine, Cyclophosphamide, Rituximab) in the CLL8 Trial of the German CLL Study Group (GCLLSG)

Anna Fink, MD, Raymonde Busch, Natali Pflug, MD, Sebastian Boettcher, MD, Dirk Winkler, MD, Andreas Buehler, MD, Matthias Ritgen, MD, Kirsten Fischer, MD, Barbara Eichhorst, MD, Clemens-Martin Wendtner, MD, Myriam Mendila, MD, Michael K. Wenger, MD, Hartmut Doehner, MD, Michael Kneba, MD, Stephan Stilgenbauer, MD, Michael Hallek, MD

Blood (2011) 118 (21): 977.

https://doi.org/10.1182/blood.V118.21.977.977

Published: 2011

Journal Articles

Genetics of Patients with F-Refractory CLL or Early Relapse After FC or FCR: Results From the CLL8 Trial of the GCLLSG

Thorsten Zenz, MD, Raymonde Busch, Anna Fink, MD, Dirk Winkler, MD, Kirsten Fischer, MD, Andreas Bühler, MD, Patrick Hoth, Gunter R. Fingerle-Rowson, MD, PhD, Michael Kneba, MD, PhD, Sebastian Boettcher, MD, Ulrich Jäger, MD, Myriam Mendila, MD, Michael Wenger, MD, Peter Lichter, PhD, Michael Hallek, MD, Hartmut Döhner, MD, Stephan Stilgenbauer, MD

Blood (2010) 116 (21): 2427.

https://doi.org/10.1182/blood.V116.21.2427.2427

Published: 2010

Journal Articles

IGHV-Mutation Status, IGHV-Gene Usage and Chromosomal Aberrations In CLL: Pooled Analysis within First-Line Clinical Trials of the German CLL Study Group (GCLLSG)

Andreas Bühler, MD, Thorsten Zenz, MD, Dirk Winkler, MD, Raymonde Busch, Kirsten Fischer, MD, Anna Fink, MD, Clemens Wendtner, Barbara Eichhorst, Jennifer Edelmann, MD, Michael Hallek, Hartmut Doehner, MD, Stephan Stilgenbauer, M.D.

Blood (2010) 116 (21): 3609.

https://doi.org/10.1182/blood.V116.21.3609.3609

Published: 2010

Journal Articles

Serum Factors Predict Therapeutic Outcome In Patients with Chronic Lymphocytic Leukemia Treated In the CLL8 Trial of the German CLL Study Group (GCLLSG)

Anna Fink, MD, Natali Pflug, MD, Raymonde Busch, Gunter R. Fingerle-Rowson, MD, PhD, Barbara Eichhorst, MD, Clemens-Martin Wendtner, MD, Dirk Winkler, MD, Andreas Buehler, MD, Myriam Mendila, MD, Michael Wenger, MD, Hartmut Dohner, MD, Stephan Stilgenbauer, M.D., Michael Hallek, MD, Kirsten Fischer, MD

Blood (2010) 116 (21): 918.

https://doi.org/10.1182/blood.V116.21.918.918

Published: 2010

NARROW

MRD-guided zanubrutinib, venetoclax, and obinutuzumab in relapsed CLL: primary end point analysis from the CLL2-BZAG trial

Prediction of Poor Outcome in CLL Patients Treated with FCR (Fludarabine, Cyclophosphamide, Rituximab) in the CLL8 Trial of the German CLL Study Group (GCLLSG)

Genetics of Patients with F-Refractory CLL or Early Relapse After FC or FCR: Results From the CLL8 Trial of the GCLLSG

IGHV-Mutation Status, IGHV-Gene Usage and Chromosomal Aberrations In CLL: Pooled Analysis within First-Line Clinical Trials of the German CLL Study Group (GCLLSG)

Serum Factors Predict Therapeutic Outcome In Patients with Chronic Lymphocytic Leukemia Treated In the CLL8 Trial of the German CLL Study Group (GCLLSG)

Email alerts

ASH Publications

American Society of Hematology

MRD-guided zanubrutinib, venetoclax, and obinutuzumab in relapsed CLL: primary end point analysis from the CLL2-BZAG trial

Prediction of Poor Outcome in CLL Patients Treated with FCR (Fludarabine, Cyclophosphamide, Rituximab) in the CLL8 Trial of the German CLL Study Group (GCLLSG)

Genetics of Patients with F-Refractory CLL or Early Relapse After FC or FCR: Results From the CLL8 Trial of the GCLLSG

IGHV-Mutation Status, IGHV-Gene Usage and Chromosomal Aberrations In CLL: Pooled Analysis within First-Line Clinical Trials of the German CLL Study Group (GCLLSG)

Serum Factors Predict Therapeutic Outcome In Patients with Chronic Lymphocytic Leukemia Treated In the CLL8 Trial of the German CLL Study Group (GCLLSG)

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only